Table 1.
Summary of the data extracted from the 16 studies included
| First author | Year | Region | Patients(n) | ASXL1 mutations, n (%) | Median age year (range) | Sex (male/female) | Diagnostic criteria |
|---|---|---|---|---|---|---|---|
| Courtier [31] | 2020 | France | 86 | 41 (48) | NA | NA | WHO |
| Gill [32] | 2019 | China | 70 | 25 (36) | 60 (26–89) | 47/23 | WHO |
| Guglielmelli [24] | 2018 | Italy | 490 | 113 (23) | 55.4 (14.0–70.0) | 284/206 | WHO |
| Guglielmelli [8] | 2017 | Italy # | 278 | 50 (18) | 56.6 (18–90.3) | 156/122 | WHO |
| 2017 | Italy * | 383 | 129 (34) | 63.6 (14–89.8) | 249/134 | WHO | |
| Yonal-Hindilerden [33] | 2015 | Turkey | 77 | 19 (25) | 60.8 | 34/43 | WHO |
| Rotunno [28] | 2019 | Italy | 333 | 119 (36) | NA | 218/115 | WHO |
| Song [29] | 2017 | USA | 45 | 18 (40) | NA | NA | WHO |
| Tefferi [25] | 2014 | USA # | 277 | 85 (31) | 64 (32–87) | 177/100 | WHO |
| 2014 | Italy* | 293 | 57 (19) | 61.8 (14–90) | 180/113 | WHO | |
| Tefferi [26] | 2016 | USA | 182 | 65 (36) | 63(22–87) | 118/64 | NA |
| Tefferi## [27] | 2018 | USA | 145 | 34 (23) | 56 (22–87) | 84/61 | WHO |
| Tefferi** [9] | 2018 | USA/Italy | 641 | 242 (38) | 63 (−) | 410/231 | WHO |
| Vallapureddy [30] | 2019 | USA | 596 | 246 (41) | NA | NA | WHO |
| Vannucchi [35] | 2013 | Europe | 483 | 105 (22) | 61 (14–90) | 296/187 | WHO |
| Wang [36] | 2020 | China | 122 | 45 (37) | 61 (21–88) | 68/54 | WHO |
#One cohort of the study; *Another cohort of the study; ##British Journal of Haematology; **Leukemia; NA, not available; WHO, World Health Organization